I am who I say I am
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Shannon seemed ill prepared or perhaps she is just a poor public speaker.
I have to say, that was the worst roadshow presentation I have ever heard and it isn't even close.
Already ending with only a few questions. Ridiculous
No uplisting on the horizon although it is a goal. LOL
Seaport Steak margins to be greater than 30%. Closing within 6 months.
LOI on acquisition in Houston. Distribution company generating revenue.
SnoBar to come back online 2023 due to new packager in Florida
Expanding in the southwest but gives zero details
I am more than happy to keep an open mind tomorrow during the call. We'll see if management gets it or not.
Good luck to all the long suffering shareholders who owned this company's stock for years.
Thanks.
I'm not sure that is the end all be all for whether SA is still dealing with Amarex though but I appreciate the reference.
You might be remembering Shannon's "recon mission" comment where she said something like we sat around the table with the Seaport Management Group management team to discuss....
Not the same as having a board of directors WITH independent members watching out for shareholders.
If Shannon and Marc want to be respected then act like a real company and show shareholders you know you have fiduciary responsibilities.
Far as I know, Shannon and Marc are the only ones calling the shots. Anyone know different?
There is no board holding the two of them accountable? It is not in shareholder's best interest for this to continue.
Are you stating SA no longer reps CYDY at all, including the Amarex matter? Who is the new firm?
LOL. I'll belive it when I see it.
"respected woman in the meat industry" has a whole other meaning when it comes to giving investors the shaft.
Shannon had better knock a grand slam on Wednesday.
Me too. What a crock that was and here we are again. Thanks PACV management!
Pump harder. The shares you are buying are paying Shannon's and Marc's bar tab at their business lunch. Probably trying to figure out how to screw investors some more.
https://finance.yahoo.com/quote/PACV/
That is a nice reminder and great for new investors. Let's see something significant come out of the roadshow presentation.
I own stock in 7 traded companies. Every single one but PACV list their officers and directors on their website.
Anyone have details on the leadership team and board members other than Shannon and Marc?
Makes sense investors would be interested in those reports.
I'm guessing the company could give a crap if we trade on the OTC ever again.
Would love to hear Altitrade Partners take on this latest development.
Absolutely.
I am interested in the investment opportunity. Obviously and rightfully so, details are not public but given Nostrum's support if needed, it sounds like an amazing opprtunity.
Looks like the investment proposal may have been finalized 6/22/22. Read the last paragraph for clarification.
Fact Sheet and investment opportunity related to Gene Bio. Received from the CEO:
The Opportunity: We are a San Diego-based, late-stage biotechnology company focused on the clinical development
and commercialization of angiogenic gene therapy biotherapeutics for strategic niche markets primarily for the
treatment of cardiovascular disease.
Our lead Generx [Ad5FGF-4], is an innovative single, one-time dose, catheter-based, treatment for patients with
refractory angina due to late-stage coronary artery disease, for use by interventional cardiology physiciansimmediately
following a standard angiogram procedure. There are an estimated 1.0 million cardiac angiograms are performed in
the U.S. each year, and an estimated 500,000 of these patients could potentially benefit from Generx therapy, at a
projected $8,000 to $10,000 per dose, representing a $4.0 to $5.0 billion total potential market opportunity for this
patient subgroup alone. There is no special training or medical devices required for physicians to integrate the use of
Generx into their daily practice. These patients have an unmet medical need, and Generx offers a new business with a
billion-dollar market opportunity for physicians.
Investors: We are a majority-owned operating subsidiary of Nostrum Pharmaceuticals LLC, a U.S.-based, privately
owned, fully integrated, pharma company, engaged in the formulation and commercialization of specialty products
and controlled-release, orally administrated, branded, and generic drug products. Nostrum operates multiple
manufacturing facilities, supported by sales, marketing and distribution activities, that sells products to hospitals and
retail drug stores, by Rx prescription only, throughout the United States. Nostrum currently owns approximately 75%
of Gene Biotherapeutics and approximately 25% is owned by public shareholders. Gene Bio investors currently own an
85% interest in Generx, and Huapont Life Sciences, a Chinese-based, publicly traded, pharmaceutical company, owns a
15% interest in Generx, and has an exclusive right to market and sell Generx in mainland China following FDA approval
of Generx in the United States
Business Strategy: Gene Bio has a cost-conserved and outsourced-service provider operating structure, supported by
Nostrum’s corporate infrastructure and capital. We have a highly experienced team thatis currently singularity focused
on (1) the manufacture of our lead product Generx [Ad5FGF-4] by
Fujifilm Diosynth Biotechnologies, located in College Park, Texas; (2) the
conduct of our final 160-patient, FDA-cleared, Phase 3 clinical study,
and (3) FDA approval. The FDA has now cleared the Generx cGMP
manufacturing specifications and Phase 3 clinical study. With the
successful completion of this final study, Gene Bio plans submit a
biologics license application to the FDA and secure FDA approval to
market and sell Generx in the United States.
Proposed Financing: We are seeking to raise up to $6.0 million in
a short-term (24 month) debt financing to support our going
forward operations as a C-Round bridge financing which will be
followed (within 12-16 months) by a planned S-1 Registration
Statement initial public financing, that is anticipated to fully fund
the Generx clinical development program. The attached term sheet
provides the terms and conditions covering this proposed financing.
Investors will have a right to receive repayment of principal and
interest at maturity or participate in the planned IPO at a significant
discountto market. Nostrum has agreed to guarantee repayment of
principal at maturity.
Fact Sheet &
Proposed IPO
Bridge C-Round
Debt Financing
The Mechanism of Action: Generx has been designed to improve cardiac perfusion by promoting the formation of
functional coronary collateral blood vessels within the heart through the enlargement of existing arterioles
(arteriogenesis) and the formation on new capillary vessels (angiogenesis). This process, termed “medical
revascularization,” represents a fundamentally new mechanism of action that involves the stimulation and formation
of new biological structures in the heart, as opposed to currently available traditional symptomatic pharmacologic
therapies, which only address the symptoms of angina, or mechanical revascularization, through procedures involving
angioplasty and stent placement or coronary artery bypass graft surgery.
Clinical Findings: The Generx regulatory dossier represents one of the most extensive and advanced gene-based clinical
data platforms ever compiled. In multiple prior clinical studies, the Generx product candidate has been evaluated in
over 650 patients (450 receiving Generx) and appears safe and well-tolerated with findings of efficacy in men and
women, in measures of cardiac perfusion, exercise capacity, and angina status. Specifically, Generx has been evaluated
as a treatment for patients with refractory angina in four prior FDA-cleared, multi-center, randomized and placebocontrolled clinical studies (AGENT 1-4, covering Phase 1|2, Phase 2 and two Phase 2b/3 clinical studies), and one small
Phase 2 international study (ASPIRE). These studies have generated over 2,500 patient years of safety data. Generx has
now been cleared by the FDA for our final Phase 3 clinical study to further evaluate safety and definitive efficacy.
U.S. Market Strategy: To support our go to market strategy, we conducted a survey of U.S. interventional cardiologists to
gauge their experience-based assessment of the prevalence of refractory angina patients, and their openness to integrate
the use of the Generx angiogenic gene therapy product candidate, upon FDA approval, into their clinical practice. The
survey confirmed that all survey physician responders see patients with long-term refractory angina as an unmet medical
need, and all were strongly positive and without reservation about the adoption of Generx following FDA approval. All
cardiologists surveyed felt there is a current need for Generx to treat refractory angina and they would consider using
Generx in their daily practice.
Competitive Factors: We believe that we have a significant clinical lead over even our nearest competitor, and that our
knowledge base, technology platform, a $200 million investment research and development spend by larger pharma
players prior to Nostrum’s acquisition, our FDA cleared treatment algorithm and business model, all represent significant
barriers to entry. Following FDA approval, we believe that Generx will potentially be considered superior in the
competitive marketplace. We believe that Generx therapy will represent a better, faster, and cheaper solution than other
therapies now in development. Our FDA-cleared Ad5FGF-4 manufacturing process offers significant gross margin
opportunities, scalable campaign manufacturing, generates a ready to use plug-n-play product, and has a well-researched
and clinically supported MOA, and receptor-based, cardiac cell targeting. We see little or no direct competition in our
space until 2030.
Potential for Exceptional ROI: With public access to capital markets and sufficient financial resources, an accelerating
Phase 3 clinical study, a NASDAQ listing with stock trading liquidity, on a post-IPO basis, we believe, that there would be
support for an intermediate market capitalization ranging from $200 million to $500 million. Based on the Company’s
business model, market opportunity, overall economics and competitive exclusivity, with the successful completion of the
Phase 3 clinical study, Gene Bio believes that there would be ample evidence to support a Generx terminal value range
of $1.0 billion to $3.0 billion, that could potentially be offered by key strategic players from the pharmaceutical and
biotechnology companies focused in the gene therapy, cardiovascular drugs and biologics and vascular access sectors
operating in the U.S. and internationally.
For additional information, please reference our Annual Report on Form 10-K, dated April 21, 2022, as filed with the SEC,
the IPO Bridge C-Round Debt financing, dated June 22, 2022, and Gene Investor Presentation, dated July 27, 2021, that is
available on the Company’s website below. In addition, please also visit Gene Bio’s website
www.GeneBiotherapeutics.com and our Phase 3 patient recruitment website at www.MyRefractoryAngina.com
12:11 is when I got the email notice from the company. That just shouldn't happen.
Take a look at the chart under her leadership. I'm not sure if she wants to tank "her company" but the chart confirms she hasn't done shareholders any favors.
Dr. Johnson –
Please accept our apologies on the delayed notification. We ran into unforeseen technical difficulties and needed to reschedule once more. The event will be held August 10th at 11:30am ET as announced in the Company’s press release.
Again, we apologize for the inconvenience.
Brooks Hamilton
MZ Group | Director – MZ North America
Main: 949-546-6326
Mobile: 206-300-6691
brooks.hamilton@mzgroup.us
Never heard a company rescheduling a presentation twice.
Another week passes by with nothing from Gene Bio and our investors from Nostrum.
If the company is selling, why should investors buy? It is one thing to raise money at reasonable prices. Another thing at a penny or two.
Management has to do better.
Disappointing price movement as of right now. Hard to explain given what the company has stated.
I had a conflict for tomorrow so I guess I am ok with the delay but...WTH is up?
LOS ANGELES, CA / July 25, 2022 / Pacific Ventures Group, Inc. (OTC PINK:PACV) (“Pacific Ventures” or the “Company”), a consumer-centric distribution company specializing in food, beverage and alcohol-related products, has rescheduled its virtual roadshow webinar to Tuesday, August 2, 2022 at 11:30 a.m. Eastern Time.
Shannon Masjedi, President and CEO of Pacific Ventures Group, will present an overview of the Company’s recent operational progress, growth initiatives, and strategic vision. The webinar will be accompanied by a presentation and followed by a question-and-answer session, which can be accessed via the webcast link or dial-in numbers below.
To access the webinar, please use the following information:
Date: Tuesday, August 2, 2022
Time: 11:30 a.m. Eastern time (8:30 a.m. Pacific time)
Dial-in: 1-877-704-4453
International Dial-in: 1-201-389-0920
Conference Code: 13731805
Webcast: Pacific Ventures Virtual Roadshow
A telephone replay will be available approximately two hours after the call and will run through Tuesday, August 30, 2022, by dialing 1-844-512-2921 from the U.S., or 1-412-317-6671 from international locations, and entering replay pin number: 13731805. The replay can also be viewed through the webinar webcast link above.
About Pacific Ventures Group, Inc.
Pacific Ventures Group, Inc. (OTC:PACV) is a consumer-centric distribution company focused on food, beverage, and alcohol-related products. Through its portfolio of operating subsidiaries, Pacific Ventures delivers specialty groceries, top quality proteins and produce, and innovative products to consumers through wholesale, retail, and direct-to-consumer channels. For more information on Pacific Ventures Group, please visit www.pacvgroup.com.
Exactly. What is the hold up? You have a $200 million company dragging their heels on raising $5-10 million to complete an extremely straight forward trial.
Thanks for doing that. Never seen an OTC traded company do less to raise awareness of their progress than PACV.
The data hasn't changed as far as the next angina study is concerned. The question is has the pre-clinical work on other indications shown promise? Also, Nostrum may have decided their resources are better spent elsewhere. Yeah they are in for several million but as a $200 million revenue company I doubt they are losing sleep over it.
I do know they appear to be in absolutely no hurry to move things along. Why?
I wonder if CRXM management is paying attention to the drama at Generex Biotechnology. It appears several creditors are looking to take over assets potentially. Gene Bio sold rights to Excellagen. About a year ago GNBT was on the cusp of kicking off sales through the VA system. Company went dark and is now facing BK. It doesn't look good that Gene Bio is ever going to see royalty payments from Generex at least.
Might want to CC the CEO:
shannon@pacvgroup.com
CytoDyn Highlights NIH Grant for HIV Functional Cure Preclinical Study of Gene Therapy Based on Leronlimab
Download as PDFJuly 11, 2022 8:30am EDT
$5 Million Grant Awarded to OHSU for Preclinical Research of One-time Injection of Gene Therapy Based on Leronlimab for Functional Cure of HIV
VANCOUVER, Washington, July 11, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced a new, preclinical study in nonhuman primates that will evaluate the potential use in HIV of a gene therapy based on the experimental monoclonal antibody leronlimab.
The research will be led by Oregon Health & Science University (OHSU) researcher Jonah Sacha, Ph.D., who also serves as a CytoDyn scientific advisor. The study is funded by a five-year grant of up to $5 million to OHSU from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH). The grant will fund the development and preclinical research of a single-injection gene therapy that codes for the leronlimab protein sequence and which will be delivered via an adeno-associated virus (AAV) vector. The study will examine if this gene-therapy approach could provide the potential for “functional cure,” i.e., sustained viral suppression to people with HIV without requiring them to take medications for the rest of their lives.
Leronlimab has demonstrated it can pharmacologically mimic a CCR5 deficient donor by occupying available CCR5 molecules.1 Leronlimab is a protein, and the goal of the research at OHSU is to create a gene therapy that expresses the gene encoding the leronlimab protein. This gene therapy will also require a new delivery modality. The grant will fund the design of synthetic novel AAV vectors specific for T and B cells, with the goal of facilitating long-term expression of leronlimab by the body’s own T and B cells. A novel AAV vector may also support the future development of other anti-HIV approaches, including CRISPR-Cas9, chimeric antigen receptors, and broadly neutralizing antibodies, as it may be able to deliver these therapeutics to the relevant immune cell type. The desired outcome of this research is the development of a safe and effective single injection that suppresses HIV replication long-term, eliminating the need for frequent dosing with antiretroviral therapy.
Jacob Lalezari, M.D., Scientific Advisor to CytoDyn, stated, “The potential for a one-time gene therapy encoding a protein such as leronlimab represents a great hope for the future of HIV therapy and functional cure. Currently, cells deficient in CCR5 have demonstrated a potential path to HIV cure, and bone marrow transplant is not an option for most patients because it is risky and highly invasive. We look forward to exploring this critical area with the assistance of the NIH and advancing research with hopes of finding a functional cure and helping to end the HIV pandemic.”
Dr. Cyrus Arman, CytoDyn’s President, said, “We are honored to have the NIH’s support for a gene therapy encoding the sequence for leronlimab, and to further the research and development of leronlimab and its derivatives. Further, we are excited about the potential for this next generation approach to HIV cure.”
About HIV Functional Cure
Worldwide, nearly 38 million people live with HIV, and about 73% of them receive treatment.2 Of the 37.9 million people living with HIV around the world, approximately 23.3 million (62%) are receiving antiretroviral therapy (ART) and have the virus under control. ART therapy, however, requires regular treatment. While accessibility to testing and treatment has significantly improved worldwide, poverty, gender equality, and HIV stigma and discrimination are significant barriers to HIV prevention and treatment in many countries.3 Over half of the people living with HIV in the United States are age 50 and older, often with multiple comorbidities including liver disease, heart disease, and cancer.4 Functional cure is where the virus is still present but it is under control without the need for ongoing treatment. The CCR5 receptor remains a top target for a functional cure.
Gene therapy consisting of the gene for an anti-HIV antibody carried by an AAV vector holds promise for long-term control of HIV. Adeno-associated viruses represent a promising vector platform, mainly due to their relative safety and ability to stimulate immune responses in multiple species.5